WATCHMAN FLX Versus NOAC for Embolic ProtectION in in the Management of Patients With Non-Valvular Atrial Fibrillation
WATCHMAN FLX Versus NOAC for Embolic ProtectION in in the Management of Patients With Non-Valvular Atrial Fibrillation
The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.
This study is a prospective, randomized, multi-center global investigation. Subjects will be randomized to either the WATCHMAN FLX Left Atrial Appendage Closure Device ("Device Group") or a commercially available non-vitamin K oral anticoagulant ("Control Group").
Inclusion Criteria:
Exclusion Criteria:
Transthoracic Echo Exclusion Criteria:
Columbus, Ohio 43214, United States
Kitakyushu-shi, Fukuoka 802-8555, Japan
Shiwa-gun, Iwate 028-3695, Japan
Chiyoda-ku, Tokyo, Japan